GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
TL;DR
GeoVax Labs' GEO-CM04S1 vaccine shows superior immune response in CLL patients, offering a competitive edge in immunocompromised populations underserved by current COVID-19 vaccines.
GEO-CM04S1 utilizes a synthetic MVA vector to express SARS-CoV-2 S and N antigens, aiming for broader and more durable immune protection in Phase 2 trials.
GeoVax's innovative vaccine could significantly improve COVID-19 protection for immunocompromised individuals, marking a step forward in global health equity and patient care.
Discover how GeoVax's GEO-CM04S1 vaccine, with its unique MVA platform, is redefining COVID-19 protection for those with chronic lymphocytic leukemia and beyond.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present significant findings from its Phase II randomized clinical trial of GEO-CM04S1, a next-generation COVID-19 vaccine candidate, at the European Hematology Association (EHA) 2025 Hybrid Congress. The data highlights the vaccine's enhanced cellular immune response in patients with chronic lymphocytic leukemia (CLL), a group known for their compromised immune responses to vaccines.
The presentation, led by Dr. Alexey V. Danilov from the City of Hope Comprehensive Cancer Center, will detail how GEO-CM04S1 outperforms authorized mRNA-based COVID-19 vaccines in eliciting immune responses among CLL patients. This development is crucial as it addresses the unmet need for effective vaccination strategies in immunocompromised individuals, offering hope for better protection against COVID-19.
GEO-CM04S1 utilizes a synthetic Modified Vaccinia Ankara (MVA) vector platform to express both spike and nucleocapsid antigens of SARS-CoV-2, aiming for broader and more durable immunity. The positive outcomes from this study could pave the way for GEO-CM04S1 to become a preferred vaccine option for vulnerable populations, including those with hematologic malignancies, who currently experience suboptimal protection from existing vaccines.
Dr. Kelly T. McKee, Jr., GeoVax's Chief Medical Officer, emphasized the importance of these findings in meeting the real-world needs of patients with compromised immune systems. The presentation at EHA 2025 underscores the potential of GeoVax's MVA multi-antigen platform in revolutionizing vaccine development for immunocompromised individuals and beyond.
Curated from NewMediaWire
